Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05400317 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy and Safety of AD-218

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 5, 2025 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Mar 31, 2025 to Mar 31, 2026
    • Study completion date: Jun 30, 2025 to Jun 30, 2026
    v4
  2. Primary completion date: May 31, 2024 to Mar 31, 2025
    • Study completion date: Oct 31, 2024 to Jun 30, 2025
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jul 18, 2022 to Jul 27, 2022
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Addpharma Inc.
28 trials monitored
See 1 trial at risk
The purpose of this study is to evaluate the efficacy and safety of AD-218
Trial Details
NCT Number NCT05400317
Lead Sponsor Addpharma Inc.
Conditions
(from sponsor)		 Mixed Dyslipidemia
Enrollment 520 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov